The Long and Winding Road

被引：1
作者：
DenBrok, Wendie [1 ]
Simmons, Christine [1 ]
Gelmon, Karen A. [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
BREAST-CANCER; POLY(ADP-RIBOSE) POLYMERASE; OVARIAN-CANCER; OPEN-LABEL; PHASE-II; EVOLUTION; RECURRENT; TUMORS; HETEROGENEITY; CHEMOTHERAPY;
D O I：
10.1200/JCO.2014.59.2311
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / U110
页数：4
相关论文
共 27 条
  • [1] [Anonymous], J CLIN ONCOL S
  • [2] The Implications of Clonal Genome Evolution for Cancer Medicine
    Aparicio, Samuel
    Caldas, Carlos
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (09) : 842 - 851
  • [3] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    Audeh, M. William
    Carmichael, James
    Penson, Richard T.
    Friedlander, Michael
    Powell, Bethan
    Bell-McGuinn, Katherine M.
    Scott, Clare
    Weitzel, Jeffrey N.
    Oaknin, Ana
    Loman, Niklas
    Lu, Karen
    Schmutzler, Rita K.
    Matulonis, Ursula
    Wickens, Mark
    Tutt, Andrew
    [J]. LANCET, 2010, 376 (9737) : 245 - 251
  • [4] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    [J]. LANCET, 2010, 376 (9742) : 687 - 697
  • [5] Tumour heterogeneity in the clinic
    Bedard, Philippe L.
    Hansen, Aaron R.
    Ratain, Mark J.
    Siu, Lillian L.
    [J]. NATURE, 2013, 501 (7467) : 355 - 364
  • [6] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    Bookman, MA
    Darcy, KM
    Clarke-Pearson, D
    Boothby, RA
    Horowitz, IR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 283 - 290
  • [7] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Bryant, HE
    Schultz, N
    Thomas, HD
    Parker, KM
    Flower, D
    Lopez, E
    Kyle, S
    Meuth, M
    Curtin, NJ
    Helleday, T
    [J]. NATURE, 2005, 434 (7035) : 913 - 917
  • [8] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
    Chapman, Paul B.
    Hauschild, Axel
    Robert, Caroline
    Haanen, John B.
    Ascierto, Paolo
    Larkin, James
    Dummer, Reinhard
    Garbe, Claus
    Testori, Alessandro
    Maio, Michele
    Hogg, David
    Lorigan, Paul
    Lebbe, Celeste
    Jouary, Thomas
    Schadendorf, Dirk
    Ribas, Antoni
    O'Day, Steven J.
    Sosman, Jeffrey A.
    Kirkwood, John M.
    Eggermont, Alexander M. M.
    Dreno, Brigitte
    Nolop, Keith
    Li, Jiang
    Nelson, Betty
    Hou, Jeannie
    Lee, Richard J.
    Flaherty, Keith T.
    McArthur, Grant A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) : 2507 - 2516
  • [9] ClinicalTrials. gov, NCT02042378 CLINICAL
  • [10] Translating cancer research into targeted therapeutics
    de Bono, J. S.
    Ashworth, Alan
    [J]. NATURE, 2010, 467 (7315) : 543 - 549
123